natgillin/translations-raw huggingface dataset:
Compared with placebo treatment, Thelin resulted in statistically significant improvement in pulmonary vascular resistance (PVR) and cardiac index (CI) after 12 weeks of treatment (see below). 
V primerjavi s placebom je zdravljenje z zdravilom Thelin po 12 tednih statistično pomembno izboljšalo pljučno vaskularno odpornost (PVR - pulmonary vascular resistance) in srčni indeks (CI - cardiac index) (glejte spodaj).
Thelin did not affect fertility in males and females. 
Zdravilo Thelin ni vplivalo na plodnost pri samcih in samicah.
•That Thelin is hepatotoxic and they will need to attend for regular blood tests 
• da je zdravilo Thelin hepatotoksično in da morajo bolniki redno prihajati na krvne preiskave;
• That treatment with Thelin often causes a decrease in haemoglobin and related red cell parameters o Need for full blood count prior to use and monitoring at clinically appropriate intervals 
• da zdravljenje z zdravilom Thelin pogosto povzroči znižanje hemoglobina in sorodnih parametrov rdečih krvnih celic o Pred začetkom jemanja je potrebno narediti krvno sliko in bolnika spremljati v klinično primernih intervalih.
In all cases, INR should be monitored on a regular schedule. 
o Vrednosti INR je potrebno skrbno spremljati.
Oral contraceptives (substrate of CYP3A4/5): Concomitant administration of Thelin and OrthoNovum 1/35 (1 mg norethindrone/ 0.035 mg ethinyl estradiol) resulted in increases in exposure to ethinyl estradiol (substrate of CYP3A4/5) and norethindrone (CYP3A4/5) of 59 % and 47%, respectively. 
Peroralna kontracepcijska sredstva (substrati CYP3A4/5): Sočasna uporaba zdravil Thelin in Ortho-Novum 1/35 (1 mg noretindrona/ 0,035 mg etinilestradiola) je povečala izpostavljenost etinilestradiolu (ki je substrat CYP3A4/5) za 59 % in noretindronu (CYP3A4/5) za 47 %.
What Thelin is and what it is used for Before you take Thelin How to take Thelin Possible side effects How to store Thelin Further information 
Kaj je zdravilo Thelin in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Thelin Kako jemati zdravilo Thelin Možni neželeni učinki
Subjects receiving warfarin achieve therapeutic anticoagulation (International Normalised Ratio [INR] target) with lower doses of the anticoagulant in the presence of sitaxentan sodium. 
Preiskovanci, ki prejemajo varfarin v prisotnosti natrijevega sitaksentanata, dosežejo terapevtsko antikoagulacijo (ciljno mednarodno normalizirano razmerje - International Normalised Ratio (INR) target) z nižjimi odmerki antikoagulacijskega sredstva.
Thelin may affect your liver. 
Zdravilo Thelin lahko vpliva na jetra.
When administered with a high fat meal, the rate of absorption (Cmax) of Thelin was decreased by 43% and the Tmax delayed (2-fold increase) compared to fasted conditions, but the extent of absorption was the same. 
Pri dajanju z obrokom, ki vsebuje veliko maščob, se v primerjavi s teščim stanjem hitrost absorpcije (Cmax) zdravila Thelin zmanjša za 43 %, Tmax pa zakasni (dvakratno povečanje), vendar je obseg absorpcije enak.
Dosage in renal impairment: No dose adjustment is required in patients with renal impairment. 
Bolniki z ledvično okvaro: Pri bolnikih z ledvično okvaro ni potrebno prilagoditi odmerka.
Sitaxentan sodium caused teratogenicity in rats (see section 5.3). 
Natrijev sitaksentanat je povzročil teratogene učinke pri podganah (glejte poglavje 5.3).
Do not take more than one tablet each day. 
Vendar ne vzemite dveh tablet v istem dnevu.
Sitaxentan sodium was detected in the plasma of breast fed pups from female rats treated with sitaxentan sodium, indicating that sitaxentan sodium was present in the breast milk. 
Natrijev sitaksentanat so odkrili v plazmi dojenih mladičev podgan, katerim so dajali natrijev sitaksentanat, kar kaže, da je natrijev sitaksentanat prisoten v materinem mleku.
Pulmonary arterial hypertension is the term used when the heart struggles to pump blood to the lungs. 
Izraz pljučna arterijska hipertenzija pomeni, da srce težko črpa kri v pljuča.
Contains lactose monohydrate 
Vsebuje laktoza monohidrat
Among patients with PAH associated with CTD in STRIDE-1 and STRIDE-2, a statistically significant difference versus placebo was observed (37.73 metres, p < 0.05). 
V skupini bolnikov s PAH povezano boleznijo vezivnega tkiva so v preskušanjih STRIDE-1 in STRIDE-2 opazili statistično pomembno razliko v primerjavi s placebom (37,73 metrov, p<0,05).
• cramp in muscles 
• krči v mišicah,
If necessary, pregnancy testing should be undertaken (see Section 
Če je potrebno, naj se izvede test nosečnosti (glejte poglavje 4.6.
Rash (various types and presentations) 
Izpuščaj (različnih vrst in kliničnih oblik)
In placebo-controlled studies, marked decreases in haemoglobin (> 15% decrease from baseline with value < lower limit of normal) were observed in 7% of patients treated with Thelin (N = 149) and 3% of placebo-treated patients (N = 155). 
V raziskavah, nadzorovanih s placebom, so izrazito znižanje vrednosti hemoglobina (>15 % znižanje od izhodiščnih vrednosti z vrednostjo < spodnje meje normalne vrednosti) opazili pri 7 % bolnikov, ki so se zdravili z zdravilom Thelin (N = 149), in 3 % bolnikov, ki so prejemali placebo (N = 155).
Due to possible teratogenicity, Thelin must not be initiated in women of child-bearing potential unless they practise reliable contraception. 
Zaradi možne teratogenosti se zdravila Thelin ne sme uvajati pri ženskah v rodni dobi, če ne uporabljajo zanesljive kontracepcije.
Thelin increases the plasma levels of Vitamin K antagonists such as warfarin, acenocoumarol and fenprocoumon (see section 4.5). 
Zdravilo Thelin zviša plazemske vrednosti antagonistov vitamina K, npr. varfarina, acenokumarola in fenprokumona (glejte poglavje 4.5).
PVC/ACLAR/paper-backed aluminium blisters containing 14 tablets. 
Pretisni omoti iz aluminija in s podlago iz PVC/ACLAR/papirja, ki vsebujejo po 14 tablet.
If liver transferase elevations are accompanied by clinical symptoms of liver injury (such as nausea, vomiting, anorexia, fever, abdominal pain, jaundice, or unusual lethargy or fatigue) or increases in total bilirubin > 2x ULN, treatment should be stopped and re-introduction of Thelin is not to be considered. 
Če zvišanje vrednosti jetrnih transferaz spremljajo klinični simptomi okvare jeter (npr. slabost, bruhanje, neješčnost, zvišana telesna temperatura, abdominalne bolečine, zlatenica ali nenavadna letargija ali utrujenost) ali če se raven skupnega bilirubina zviša > 2 × ZMN, je potrebno zdravljenje prekiniti in zdravljenja z zdravilom Thelin ne smete ponovno uvesti.
In PAH and heart failure, in the absence of endothelin receptor antagonism, elevated ET-1 concentrations are strongly correlated with the severity and prognosis of these diseases. 
Zvišane koncentracije ET-1 pri PAH in srčnem popuščanju ter v odsotnosti antagonizma receptorja za endotelin so močno povezane z resnostjo in prognozo teh bolezni.
Predominant actions of ET-1 binding to ETA are vasoconstriction and vascular remodelling, while binding to ETB results in ET-1 clearance, and vasodilatory/ antiproliferative effects due in part to nitric oxide and prostacyclin release. 
Ko se ET-1 veže na ETA, sta posledici v glavnem vazokonstrikcija in vaskularno remodeliranje, vezava ET-1 na ETB pa povzroči očistek ET-1 in vazodilatorne/antiproliferativne učinke, ki so deloma posledica sproščanja dušikovega oksida in prostaciklina.
Symptomatic hepatitis 
Simptomatski hepatitis redki
No data are available with Thelin in patients with pulmonary hypertension associated with pulmonary veno-occlusive disease. 
Ni podatkov o uporabi zdravila Thelin pri bolnikih s pljučno hipertenzijo, ki je povezana s pljučno veno-okluzivno boleznijo.
Thelin should be used with caution if you are taking or begin to take Vitamin K antagonists (e.g. warfarin, acenocoumarol, fenprocoumon or fluindione). 
Zdravilo Thelin morate jemati previdno, če jemljete ali ste začeli jemati antagoniste vitamina K (npr. varfarin, acenokumarol, fenprokumon ali fluindion).
In these studies, the study medicine was added to patients' current therapy, which could have included a combination of digoxin, anticoagulants, diuretics, oxygen, and vasodilators (eg, calcium channel blockers, ACE inhibitors). 
V omenjenih raziskavah so preučevano zdravilo dodali bolnikovi obstoječi terapiji, ki je lahko vključevala kombinacijo digoksina, antikoagulacijskih sredstev, diuretikov, kisika in vazodilatorjev
Liver aminotransferase elevations may reverse spontaneously while continuing treatment with sitaxentan sodium. 
Zvišane vrednosti jetrnih aminotransferaz se lahko vrnejo v normalno območje spontano v nadaljevanju zdravljenja z natrijevim sitaksentanatom.
Thelin comes in blister packs of 14, 28, 56, and 84 tablets and bottles of 28 tablets. 
Zdravilo Thelin je na voljo v pretisnih omotih s 14, 28, 56 in 84 tabletami ter plastenkah z 28 tabletami.
HOW TO TAKE THELIN 
KAKO JEMATI ZDRAVILO THELIN
Thelin should not be used during pregnancy unless clearly necessary ie, in case no alternative treatment options are available. 
Zdravilo Thelin ne smete uporabljati med nosečnostjo, razen če je nujno potrebno, tj. če ni na voljo drugega načina zdravljenja.
The influence of liver impairment on the pharmacokinetics of sitaxentan sodium has not been evaluated. 
Okvara jetrne funkcije Vpliv okvare jeter na farmakokinetiko natrijevega sitaksentanata ni raziskan.
At high doses, dose-related increases in prothrombin time (PT) and activated partial thromboplastin time (APTT) were also seen, most prominently in rats, and coagulopathy (bleedings) in rats and dogs, but not mice. 
Pri visokih odmerkih so zlasti pri podganah opazili od odmerka odvisno podaljšanje protrombinskega časa (PČ) in aktiviranega parcialnega tromboplastinskega časa (APTČ), pri podganah in psih pa koagulopatijo (krvavitve), česar niso opazili pri miših.
Thelin 100 mg film-coated tablets 
Thelin 100 mg filmsko obložene tablete
Pulmonary veno-occlusive disease (PVOD) 
Pljučno veno-okluzivna bolezen
Consequently, should signs of pulmonary oedema occur when Thelin is administered in patients with pulmonary hypertension, the possibility of associated veno-occlusive disease should be considered. 
Če se pojavijo znaki pljučnega edema pri bolnikih s pljučno hipertenzijo, ki jemljejo zdravilo Thelin, je treba upoštevati možnost povezane veno-okluzivne bolezni.
Thelin tablets contain lactose monohydrate. 
Tablete Thelin vsebujejo laktozo monohidrat.
Name and address of the manufacturers responsible for batch release 
Ime in naslov izdelovalcev odgovornih za sproščanje serije
The placebo-corrected increases in walk distance in the whole cohort compared to baseline were 35 metres (p = 0.006; ANCOVA) and 31 metres (p < 0.05; ANCOVA), respectively. 
Po korekciji s skupino bolnikov, ki je prejemala placebo, je bila prehojena razdalja v celi skupini v primerjavi z izhodiščem v prvi raziskavi daljša za 35 metrov (p=0,006; ANCOVA), v drugi raziskavi pa daljša za 31 metrov (p<0,05; ANCOVA).
There is no specific experience with the management of Thelin overdose. 
Specifičnih izkušenj o obravnavi prevelikega odmerjanja zdravila Thelin ni.
•The need to tell their doctor about any adverse events 
• da morajo bolniki obvestiti svojega zdravnika o neželenih učinkih;
Administration of Thelin to female rats from late-pregnancy through lactation reduced pup survival, and caused testis tubular aplasia and delayed vaginal opening at the lowest exposure tested (17-45 times the human exposure). 
Dajanje zdravila Thelin podganjim samicam od pozne brejosti ter skozi dojenje je pri najnižjem preskušenem odmerku (17-45-kratni izpostavitvi pri človeku) zmanjšalo preživetje mladičev in povzročilo testikularno tubularno aplazijo ter zakasnjeno odpiranje nožnice.
Liver aminotransferases increase, bilirubin increase (associated with liver aminotransferase increase) 
Bolezni jeter, žolčnika in žolčevodov Zvišanje jetrnih aminotransferaz, zvišanje bilirubina (povezano z zvišanjem jetrnih aminotransferaz)
Warfarin (vitamin K antagonist, substrate of CYP2C9): Concomitant treatment with sitaxentan sodium resulted in a 2.4 fold increase in S-warfarin exposure. 
Varfarin (antagonist vitamina K, substrat CYP2C9): Sočasno zdravljenje z natrijevim sitaksentanatom je povzročilo 2,4-kratno zvišanje izpostavitve S-varfarinu.
Sitaxentan sodium is rapidly absorbed following oral administration. 
Natrijev sitaksentanat se hitro absorbira po peroralni uporabi.
Effects of other medicinal products on Thelin 
Učinki drugih zdravil na zdravilo Thelin
In phase 2 and 3 oral studies in patients with PAH, elevations in ALT and/or AST > 3 ULN were observed in 5% of placebo-treated patients (N = 155) and 7% of Thelin 100 mg-treated patients (N = 887). 
V fazah 2 in 3 raziskav peroralne oblike pri bolnikih s pljučno arterijsko hipertenzijo so zvišanje vrednosti ALT in/ali AST > 3 ZMN zabeležili pri 5 % bolnikov, ki so jemali placebo (N=155) in pri 7 % bolnikov, ki so jemali zdravilo Thelin 100 mg (N=887).
• bleeding from the gums 
• krvavitve iz dlesni
Digoxin (substrate of p-Glycoprotein): Concomitant administration of Thelin did not alter the pharmacokinetics of digoxin indicating no effect on the p-glycoprotein transporter 
Digoksin (substrat p-glikoproteina): Sočasna uporaba zdravila Thelin ne spremeni farmakinetike digoksina, kar kaže, da ni vpliva na transporter p-glikoproteina.
Recommendations in case of treatment-emergent ALT/AST elevations: If ALT/AST measurements rise to the following levels then changes to the monitoring or treatment are given: 
Če se vrednosti ALT/AST zvišajo na navedene vrednosti, potem se priporočajo naslednje spremembe spremljanja ali zdravljenja:
If you miss a dose, take the missed dose as soon as you remember but do not take two tablets in one day. 
Če ste pozabili vzeti odmerek, vzemite pozabljeni odmerek, ko se spomnite.
STRIDE-1, which included 178 patients, compared 2 oral doses of Thelin (100 mg once daily and 300 mg once daily) with placebo during 12 weeks of treatment. 
V preskušanju STRIDE-1, kjer je bilo vključenih 178 bolnikov, so primerjali 2 peroralna odmerka zdravila Thelin (100 mg enkrat dnevno in 300 mg enkrat dnevno) s placebom v 12 tednih zdravljenja.
The most common metabolic products are at least 10 times less potent as ETA antagonists than sitaxentan sodium in a standard in vitro test of activity. 
Najpogostejši presnovni produkti so bili v standardnem in vitro testu aktivnosti najmanj 10-krat manj učinkoviti antagonisti ETA kot natrijev sitaksentanat.
• When new information is received that may impact on the current Safety Specification, 
• kadar imetnik dovoljenja za promet z zdravilom prejme nove informacije, ki lahko vplivajo na trenutne specifikacije varnosti zdravila, načrt farmakovigilance ali na dejavnosti za zmanjšanje tveganja
The information collected should include: o Anonymised patient details - age, sex and aetiology of PAH o Concomitant medications o Reason for discontinuation o ADRs o All serious ADRs o Increase in hepatic enzymes to > 3 × ULN o Elevated direct bilirubin > 2 ×ULN o Anaemia o Haemorrhage o Pregnancy and outcome o Pulmonary oedema (associated with veno-occlusive disease) o Suspected interactions o Unexpected ADRs according to the SPC. 
Zbrani podatki morajo vsebovati: o anonimizirane podatke o bolniku - starost, spol in etiologijo PAH, o sočasna zdravljenja, o razloge za ukinitev, o neželene učinke, ○ vsi resni neželeni učinki, ○ povišani jetrni encimi na > 3 × ZMN, ○ povišani direktni bilirubin > 2 × ZMN, ○ anemija, ○ krvavitev, ○ nosečnost in izid, ○ pljučni edem (povezan z vensko-okluzivno boleznijo), ○ možna medsebojna delovanja, ○neželeni učinki, ki niso navedeni v povzetku glavnih značilnosti zdravila
At the recommended dose during placebo-controlled trials in pulmonary arterial hypertension PAH, the most common adverse drug reactions considered to be at least possibly related to Thelin treatment were headache in 15% of patients, and peripheral oedema and nasal congestion, each in 9% of patients. 
V preskušanjih, nadzorovanih s placebom, so bili pri bolnikih s pljučno arterijsko hipertenzijo (PAH), ki so jemali priporočeni odmerek, najpogostejši neželeni učinki, ki so lahko povezani z zdravljenjem z zdravilom Thelin, glavobol pri 15 % bolnikov in periferni edem ter zamašen nos, vsak pri 9 % bolnikov.
Oral contraceptive agents 
Peroralni kontraceptivi
When initiating vitamin K antagonist therapy in a patient taking sitaxentan sodium, it is recommended to start at the lowest available dose. 
Pri uvedbi zdravljenja z antagonisti vitamina K pri bolnikih, ki jemljejo natrijev sitaksentanat, je priporočljivo začeti z najnižjim odmerkom, ki je na voljo.
Concomitant administration with ciclosporin A (see section 4.5). 
Sočasno dajanje ciklosporina A (glejte poglavje 4.5).
During clinical trials, Thelin was given as a daily oral dose of 1000 mg/day for 7 days to healthy volunteers. 
V kliničnih preskušanjih so zdravi prostovoljci 7 dni prejemali peroralni dnevni odmerek zdravila Thelin 1000 mg/dan.
Elevated direct bilirubin > 2 x ULN prior to initiation of treatment. 
Zvišana vrednost direktnega bilirubina > 2 × ZMN pred začetkom zdravljenja.
He or she may want you to stop taking Thelin. 
Morda bo želel/a, da prekinete zdravljenje z zdravilom Thelin.
Appropriate care should be exercised when initiating sitaxentan in patients who discontinued other endothelin receptor antagonists due to liver enzyme abnormalities (see section 4.8). 
V primeru uvedbe sitaksentana pri bolnikih, ki so nehali uporabljati druge antagoniste receptorje za endotelin, zaradi nenormalnosti pri pri jetrnih encimih, je potrebna ustrezna previdnost (glejte poglavje 4.8).
Systemic vascular resistance (-276 dynes*sec/cm 
Po 12 tednih se je izboljšala sistemska vaskularna odpornost -276 din*s/cm
If AST and/or ALT are > 3 x ULN prior to initiation of therapy, or direct bilirubin is > 2 x ULN, use of sitaxentan is contraindicated (see section 4.3) 
Če so pred začetkom zdravljenja vrednosti AST in/ali ALT > 3 × ZMN, ali direktnega bilirubina > 2 × ZMN, je uporaba sitaksentana kontraindicirana (glejte poglavje 4.3).
System Organ Class / Adverse reaction 
Organski sistem/neželeni učinek
Film-coated tablet Capsule shaped yellow-to-orange film-coated tablets, debossed with T-100 on one side. 
filmsko obložena tableta Rumene do oranžne filmsko obložene tablete v obliki kapsule z vrezanim napisom T-100 na eni strani.
In an open-label PAH study, one fatal case of hepatic failure has been reported after chronic dosing of sitaxentan at 600 mg/day administered as 300 mg bid. 
V odprti študiji PAH je bil opisan en smrten primer odpovedi jeter po kronični uporabi sitaksentana 600 mg/dan (uporabljenega kot 300 mg dvakrat na dan).
Treatment with Thelin was associated with a dose-related decrease in haemoglobin (see section 4.8). 
Zdravljenje z zdravilom Thelin je povezano z znižanjem vrednosti hemoglobina, ki je odvisno od odmerka (glejte poglavje 4.8).
Do not use Thelin after the expiry date which is stated on the blister pack, bottle or carton after EXP. 
Zdravila Thelin ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pretisnem omotu, plastenki ali škatli poleg oznake EXP. Datum izteka roka uporabnosti se nanaša na zadnji dan navedenega meseca.
Women should not breastfeed while using Thelin. 
Ženske v času zdravljenja z zdravilom Thelin ne smejo dojiti.
Co-administration with drugs metabolized by CYP2C19 or CYP3A4/5 is not expected to result in clinically significant drug interactions. 
Ni pričakovati, da bi sočasna uporaba zdravil, ki jih presnavlja CYP2C19 ali CYP3A4/5, povzročila klinično pomembno interakcijo med zdravili.
• If you are breast-feeding (please read the section ‘Pregnancy and breast-feeding' below); 
• Če dojite (preberite poglavje „Nosečnost in dojenje“ v nadaljevanju).
• feeling and/or being sick, difficulty in passing stools, stomach ache, indigestion and diarrhoea 
• občutek slabosti ali slabost, težavno iztrebljanje, bolečine v trebuhu, prebavne motnje in driska,
No unexpected accumulation in the plasma was observed after multiple dosing at the recommended dose of 100 mg once daily. 
Po večkratnem odmerjanju priporočenega odmerka 100 mg enkrat dnevno niso opazili nepričakovanega kopičenja v plazmi.
The extent of interaction with other OATP inhibitors (some HMG CoA reductase inhibitors eg, atorvastatin, protease inhibitors eg, ritonavir, tuberculostatics eg, rifamycin) is unknown but could result in raised plasma levels of sitaxentan. 
Obseg interakcij z drugimi zaviralci OATP (nekaterimi zaviralci HMG CoA reduktaze, npr. atorvastatinom; zaviralci proteaz, npr. ritonavirjem; tuberkulostatiki, npr. rifamicinom) ni znan, vendar bi lahko povzročilo zvišanje koncentracije sitaksentana v plazmi.
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines. 
Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta in vključno z zeliščnimi pripravki ter vitamini.
In the 26-week study, moderate to marked diffuse seminiferous tubular atrophy was present at a very low incidence, whereas in the 99-week study there was a dose-related, slightly increased incidence of minimal to mild focal atrophy at doses providing 29 to 94 times the human exposure. 
V raziskavi, ki je trajala 99 tednov, so opazili od odmerka odvisno rahlo zvišano pojavnost minimalne do blage žariščne atrofije, in sicer pri odmerkih, ki so ustrezali od 29- do 94-kratni izpostavitvi pri človeku.
Functional Class: A reduction in symptoms of PAH were observed with sitaxentan sodium 100 mg treatment. 
Funkcionalni razred: Pri zdravljenju s 100 mg odmerkom natrijevega sitaksentanata so opazili zmanjšanje simptomov PAH.
INR increase (with concomitant vitamin K antagonist therapy). 
Povečanje INR (med sočasnim zdravljenjem z antagonistom vitamina K).
Long-term survival:There are no randomised studies to demonstrate beneficial effects on survival of treatment with sitaxentan sodium. 
Randomizirane raziskave, ki bi pokazale koristne učinke na preživetje zdravljenja z natrijevim sitaksentanatom, niso bile opravljene.
However, cases of life threatening pulmonary oedema have been reported with vasodilators (mainly prostacyclin) when used in those patients. 
Vendar so poročali, da je pri uporabi vazodilatatorjev (v glavnem prostaciklina) pri teh bolnikih v posameznih primerih prišlo do življenjsko ogrožajočega pljučnega edema.
Common side effects (likely to affect more than 1 in every 100 people): 
Pogosti neželeni učinki (se verjetno pojavijo pri več kot 1 od 100 bolnikov) so:
Omeprazole (substrate of CYP2C19): Concomitant administration of Thelin with omeprazole increased the omeprazole AUC0-24 by 30%; Cmax was unchanged. 
Omeprazol (substrat CYP2C19): Sočasna uporaba zdravila Thelin z omeprazolom zviša AUC0-24 omeprazola za 30 %; Cmax se ne spremeni.
The following two blood tests will be carried out before you first take Thelin and at intervals during treatment 
Preden boste prvič vzeli zdravilo Thelin, boste opravili naslednji dve preiskavi krvi in nato še v določenih časovnih presledkih med zdravljenjem.
Most of this decrease of haemoglobin concentration was detected during the first few weeks of treatment and haemoglobin levels stabilized by 4 weeks of Thelin treatment. 
V večini primerov je bilo to znižanje koncentracije hemoglobina odkrito v prvih nekaj tednih zdravljenja.
In vitro studies using human liver microsomes or primary hepatocytes show that sitaxentan sodium inhibits CYP2C9, and, to a lesser extent, CYP 2C8, CYP2C19 and CYP3A4/5. 
Podatki in vitro poskusov na človeških jetrnih mikrosomih ali primarnih hepatocitih kažejo, da natrijev sitaksentanat zavira CYP2C9 in v manjši meri tudi CYP 2C8, CYP2C19 ter CYP3A4/5.
Nausea, constipation, upper abdominal pain, vomiting, dyspepsia and diarrhoea 
Bolezni prebavil Navzea, zaprtje, abdominalna bolečina, bruhanje, dispepsija in driska pogosti